Galactosemia Animal Model Service
Galactosemia is a rare autosomal recessive disorder of galactose metabolism caused by deficiencies in one of three key enzymes: galactose-1-phosphate uridylyltransferase (GALT), galactokinase (GALK1), or UDP-galactose-4'-epimerase (GALE). The resulting accumulation of galactitol and galactose-1-phosphate leads to hepatorenal injury, cognitive impairment, and ovarian dysfunction in humans. At Protheragen, we provide specialized, customizable galactosemia animal models to support your preclinical research. Leveraging our expertise in disease modeling and translational science, we offer tailored solutions, from model selection and characterization to full pharmacokinetic and safety profiling, accelerating your drug discovery pipeline.
Overview of Galactosemia Animal Models
Galactosemia is a rare, hereditary disorder of carbohydrate metabolism primarily caused by deficiencies in the enzymes responsible for converting galactose to glucose via the Leloir pathway. The most severe and prevalent form, classic galactosemia, stems from mutations in the galactose-1-phosphate uridylyltransferase (GALT) gene, leading to the toxic accumulation of galactose-1-phosphate and galactitol in systemic tissues. If left untreated, it results in acute, life-threatening neonatal complications, while long-term survivors frequently suffer from cognitive deficits, motor speech disorders, and ovarian insufficiency despite strict dietary galactose restriction.
Fig.1 Schematic representation of the subfertility phenotype induced by GALT deficiency in a mouse model. (Balakrishnan, B., et al., 2019)
Animal models, particularly rodents, faithfully recapitulate the biochemical, metabolic, and phenotypic hallmarks of human galactosemia. These models have been extensively validated to reflect the multisystem pathology of the disease, including elevated galactose and galactitol accumulation in plasma and target tissues, progressive hepatorenal histopathological changes, and persistent neurodevelopmental deficits. As such, they serve as a robust and translational platform for mechanistic studies exploring disease pathogenesis and for therapeutic evaluation of emerging interventions, including enzyme replacement therapy, gene therapy, and small-molecule pharmacological agents.
Our Services
By combining deep preclinical expertise with a state-of-the-art vivarium infrastructure, Protheragen offers comprehensive, end-to-end galactosemia animal model services designed to meet the specific demands of drug discovery and IND-enabling studies. Our approach ensures high-fidelity disease replication through validated modeling strategies, rigorous quality control at every stage of model generation and maintenance, and deep phenotypic characterization using standardized, reproducible assays tailored to your unique investigative goals. Every step, from model design and experimental execution to data delivery, is aligned with regulatory expectations for preclinical research.
Animal Models of Galactosemia
To address the diverse mechanistic needs of preclinical pipelines, customized model development services are available across multiple validated platforms, establishing precise in vivo environments that mirror specific human enzymatic deficiencies. By tailoring structural and genetic parameters, these custom-built research assets allow for the targeted evaluation of unique therapeutic modalities.
Advanced gene-editing methodologies are utilized to generate precise germline modifications that ablate or mutate specific enzymes within the Leloir pathway. These tailor-made genetic models accurately replicate the persistent biochemical alterations, systemic toxicity, and tissue-specific pathologies critical for validating gene therapies, enzyme replacements, and small-molecule interventions.
- GALT Knockout Mouse Model: Replicates the complete loss of galactose-1-phosphate uridylyltransferase activity, leading to marked elevations of endogenous galactose-1-phosphate in systemic tissues and simulating classic galactosemia pathology.
- GALE Knockout Mouse Model: Replicates the complete loss of epimerase activity, leading to variable accumulation of metabolites and modeling mild to intermediate galactosemia variants.
- GALK1 Deficient Mouse Model: Replicates the complete loss of galactokinase 1 function, leading to high systemic galactose levels and distinct ocular phenotypes without the acute cellular toxicity from downstream metabolite accumulation.
Specialized dietary formulation strategies are deployed to introduce high-galactose exposure in wild-type cohorts, driving robust metabolic phenotypes through exogenous loading. This modeling approach provides a highly controllable system for studying secondary complications, systemic oxidative stress, and tissue degeneration.
- High-Galactose Dietary Rodent Model Development: Utilizes customized high-fraction galactose diets to systematically induce systemic metabolic stress and advanced glycation end-product accumulation in standard background strains.
Mouse Model for Galactosemia Research
| Model Name | Modeling Method | Detailed Description |
|---|---|---|
| Galt-KO Mouse Model | Knockout (KO) | Exons 3 through 9 of the Galt gene were deleted via gene targeting strategies, resulting in a loss of GALT enzyme activity. This constitutive knockout model recapitulates the classic galactosemia phenotype. |
| Gale-KO Mouse Model | Knockout (KO) | Exons 2 through 8 of the Gale gene were targeted for deletion using gene targeting strategies. Disruption of the Gale locus leads to UDP-galactose-4'-epimerase deficiency, modeling intermediate galactosemia variants. |
| Galk1-KO Mouse Model | Knockout (KO) | Exon 2 of the Galk1 gene was deleted to generate a Galk1 knockout mouse line. The absence of galactokinase activity results in marked galactitol accumulation and cataract formation, suitable for studying galactosemia type II. |
| … | … | … |
Case Study-Galt-KO Mouse Model Development
Model Introduction
The Galt-knockout mouse model was developed to recapitulate the enzyme deficiency underlying classic galactosemia. This model lacks functional galactose-1-phosphate uridylyltransferase (GALT), leading to accumulation of toxic metabolites upon galactose exposure. The model serves as a relevant platform for evaluating therapeutic interventions, including enzyme replacement and gene therapy, and for studying long-term complications such as hepatorenal dysfunction and neurodevelopmental deficits.
Methodology
- Animal Model: Exons 3 through 9 of the Galt gene were targeted for deletion to generate a knockout mouse line. The targeting construct was introduced into embryonic stem cells, and correctly targeted clones were used to produce chimeric mice. Germline transmission was confirmed, and heterozygous breeding pairs were established to generate homozygous Galt-KO animals. All animals were maintained on a standard chow diet without galactose supplementation unless otherwise specified. Genotyping was performed by PCR to verify the absence of the targeted exons.
- Phenotypic Analysis Methods: Body weight was recorded weekly from weaning through 12 weeks of age for both male and female Galt-KO mice and wild-type littermate controls. Litter size was measured as the average number of pups born per litter from each genotype. For metabolite assessment, plasma and tissue galactose-1-phosphate and galactitol levels were quantified using standard enzymatic or chromatographic methods.
Phenotypic Analysis & Results
Galt-KO mice exhibited a statistically significant reduction in body weight gain compared to wild-type littermates, starting at 4 weeks of age and persisting through the 12-week observation period. Additionally, homozygous knockout females showed reduced fertility, reflected in a smaller average litter size relative to wild-type breeding pairs. These findings are consistent with the growth retardation and reproductive abnormalities observed in human galactosemia patients. No overt motor or behavioral deficits were detected under standard housing conditions without dietary galactose challenge.
Fig.2 Comparison of body weight and average litter size between Galt-KO mice and wild-type (WT) controls. Data are presented as mean ± SEM (n=5; *p < 0.05).
Conclusion
The Galt-KO mouse model successfully recapitulated key phenotypic features of classic galactosemia, including reduced body weight gain and diminished litter size. These findings closely mirror the growth restriction and reproductive impairments observed in human patients, supporting the translational relevance of the model. The deletion of exons 3-9 effectively disrupted GALT activity, leading to a stable and reproducible phenotype suitable for preclinical efficacy and safety studies. This model is now available for custom drug development projects, including pharmacokinetic assessments, safety evaluations, and biomarker analyses, upon request.
Contact Us
Protheragen integrates galactosemia models into a full-service offering that includes pharmacokinetic studies, such as plasma and tissue clearance of galactose and its metabolites, bioavailability, and accumulation profiles, as well as comprehensive safety evaluations, including acute and repeated-dose toxicology, detailed histopathology, and clinical chemistry analysis. Our experienced team supports route-of-administration optimization, dose-finding studies, and biomarker discovery and validation. For detailed discussions regarding your specific research needs or to initiate a collaborative study, please contact us. Let us tailor a galactosemia model solution that precisely meets the requirements of your preclinical program.
References
- Balakrishnan, B et al. "Salubrinal enhances eIF2α phosphorylation and improves fertility in a mouse model of Classic Galactosemia." Biochimica et biophysica acta. Molecular basis of disease 1865.11 (2019): 165516.
- Balakrishnan, Bijina et al. "Whole-body galactose oxidation as a robust functional assay to assess the efficacy of gene-based therapies in a mouse model of Galactosemia." Molecular therapy. Methods & clinical development 32.1 (2024) 101191.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.